2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2738 Real-world use of blinatumomab and inotuzumab ozogamicin among older adults with Philadelphia-chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) in the United States

Cristian Camilo Taborda, MD, Rong Wang, PhD2, Lourdes Mendez, MD, Ph D3, Rory Shallis I, MD4, Xiaomei Ma, MD, PhD5, Nikolai Podoltsev, MD, PhD6
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Public Health, New Haven, Connecticut, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Yale School of Public Health, New Haven, Connecticut, United States
6 Yale School of Medicine, New Haven, Connecticut, United States

Introduction: Older patients (pts) with B-ALL often cannot tolerate intensive chemotherapy and have poor outcomes. Although immunotherapy with Blinatumomab (Blina; FDA-approved in 2014) and inotuzumab ozogamicin (InO; FDA-approved in 2017) have expanded treatment options for older pts, both are often not used as frontline therapy. We leveraged Surveillance, Epidemiology, and End Results program (SEER)-Medicare database to evaluate patterns, predictors, and outcomes of Blina and InO (novel agent) use among older pts with B-ALL.

Methods: We conducted a retrospective cohort study of Medicare beneficiaries aged ≥ 66 years who were diagnosed with B-ALL (International Classification of Diseases for Oncology, 3rd Edition, histology codes 9811 and 9813–9819) during 2015-2021, with follow-up through December 31, 2022. Eligible pts had continuous Medicare Parts A and B coverage and no health maintenance organization enrollment during the 12 months before diagnosis and throughout follow-up. The final cohort was restricted to pts who initiated systemic therapy within 90 days of diagnosis.

Novel agent exposure was defined as receipt of either Blina or InO at any time after diagnosis. We evaluated temporal trends in novel agent use and time from diagnosis and initial systemic therapy to novel agent initiation. Multivariable logistic regression was used to identify predictors of novel agent use. To address confounding and balance baseline characteristics between pts who did or did not receive novel agents, we performed propensity score (PS) matching. PSs were developed using logistic regression. Pts who received novel agents (i.e., users) were matched to non-users in a 1:3 ratio using a greedy nearest-neighbor matching algorithm, bounded by a caliper of 0.25 standard deviations of the logit of the PS. Median overall survival (OS) was estimated using Kaplan-Meier curves and compared between groups with log-rank tests. Survival analysis was conducted using Cox proportional hazards regression, with novel agent use modeled as a time-dependent variable to account for immortal time bias. We applied robust sandwich variance estimators clustered by match identifier to adjust for the correlated nature of the matched cohorts.

Results: The study included 501 pts with a median follow-up of 1.17 years (interquartile range [IQR]: 0.42–2.50). Median age was 73 years (IQR: 69–78), 79.4% were non-Hispanic White, and 59.5% resided in large metropolitan areas.

Overall, 124 (24.8%) pts received novel agents; Blina was the first novel agent received by 68 and Ino by 56. Among 24 pts who received both agents, 11 received Blina first and 13 received InO first. Baseline sociodemographic and clinical characteristics were similar between novel agent users and non-users. Median time from diagnosis and from systemic therapy initiation to novel agent use was 4.7 months (IQR: 2.8-11.0) and 3.9 months (IQR 2.0-9.9), respectively. Timing was similar between pts who received Blina or Ino first, measured from diagnosis (median 4.4 vs. 5.5 months, P=0.81) or initial systemic therapy (3.7 vs. 4.4 months, P=0.87).

Novel agent use increased from 11.8% in 2015 to 38.8% in 2021 (P for trend <.01).  In the multivariable model, the odds of novel agent use increased 34% per diagnosis year (odds ratio = 1.34, 95% confidence [CI] 1.19-1.51; P<0.01). No other baseline sociodemographic or clinical factors were significantly associated with novel agent use.

The PS-matched cohort included 123 novel agent users and 281 non-users. In unadjusted analyses, novel agent use was associated with longer median OS compared to non-use (2.68 vs 0.97 years; log-rank P < 0.01). However, after accounting for immortal time bias by modeling novel agent use as a time-dependent variable, the difference in OS between the two groups was no longer significant (hazard ratio = 1.24, 95% CI: 0.92–1.69; P = 0.16).

Conclusions: The use of Blina and InO increased over time, but most treated older pts did not receive either agent. Among those who did, novel agents were generally initiated months after initial systemic therapy, and receipt was not associated with survival after accounting for the timing of treatment. These findings suggest that later incorporation may limit the benefit of novel agents and highlight the need to incorporate them earlier in the treatment of older adults with Ph-negative B-ALL.

Cristian Camilo Taborda, MD: No relevant conflicts of interest to declare.